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Abstract
Background Inducible T cell co-stimulator (ICOS) deficiency has been categorized as a combined immunodeficiency often
complicated by enteropathies, autoimmunity, lymphoproliferation, and malignancy. We report seven new patients and four novel
ICOS mutations resulting in a common variable immunodeficiency (CVID)–like phenotype and show that dysregulated IL-12
release, reduced cytotoxic T lymphocyte–associated protein 4 (CTLA4) expression, and skewing towards a Th1-dominant
phenotype are all associated with inflammatory complications in this condition.
Methods A combination of whole exome and Sanger sequencing was used to identify novel mutations. Standard clinical and
immunological evaluation was performed. FACS and ELISA-based assays were used to study cytokine responses and
ICOS/ICOSL/CTLA4 expression following stimulation of whole blood and PBMCs with multiple TLR ligands, anti-CD3,
and PHA.
Results Four novel ICOSmutations included homozygous c.323_332del, homozygous c.451C>G, and compound heterozygous
c.58+1G>A/c.356T>C. The predominant clinical phenotype was that of antibody deficiency associated with inflammatory
complications in 4/7 patients. Six out of seven patients were treated with immunoglobulin replacement and one patient died
from salmonella sepsis. All patients who were tested showed reduced IL-10 and IL-17 cytokine responses, normal IL-1β, IL6,
and TNF release following LPS stimulation and highly elevated IL-12 production in response to combined LPS/IFNγ
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stimulation. This was associated with skewing of CD4+ T cells towards Th1 phenotype and increased expression of ICOSL on
monocytes. Lastly, reduced CTLA4 expression was found in 2 patients. One patient treated with ustekinumab for pancytopenia
due to granulomatous bone marrow infiltration failed to respond to this targeted therapy.
Conclusions ICOS deficiency is associated with defective T cell activation, with simultaneously enhanced stimulation of mono-
cytes. The latter is likely to result from a lack of ICOS/ICOSL interaction which might be necessary to provide negative feedback
which limits monocytes activation.
Keywords Primary immunodeficiency . granulomatous inflammation . chronic diarrhea . antibodydeficiency . ICOSdeficiency .
ustekinumab
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Introduction
Inducible T cell co-stimulator (ICOS) is a member of the
CD28/CTLA4 family, which plays an important role in regu-
lating T cell–mediated immune responses as a secondary co-
stimulatory signal delivered in concert with T cell receptor
stimulation [1, 2]. Unlike CD28, ICOS is not constitutively
expressed, but it is exclusively upregulated on activated T
cells. Although these two co-stimulatory molecules share sev-
eral intracellular signaling pathways [3, 4], their functions are
only partially overlapping, including cell survival, prolifera-
tion, and differentiation. Several in vitro and animal studies
have shown important roles of ICOS in the induction and
regulation of Th1, Th2, and Th17 immunity [5, 6]. Other
effects of ICOS on the immune system are further determined
by the cellular location of its unique ligand (ICOSL), which
has a broad tissue expression including immune cells such as
monocytes, dendritic cells, and B cells [7–9]. In the latter,
ICOS/ICOSL interaction and the ensuing cytokine production
contributes to immunoglobulin (Ig) production and long-lived
switched memory/plasma cell development within germinal
centers [10].
ICOS deficiency has been categorized as a combined im-
munodeficiency [11] and the clinical features include
hypogammaglobulinemia, vulnerability to infections, enter-
opathies, autoimmunity, lymphoproliferation, and malignancy
[12–17]. Although ICOS was the first described gene associ-
ated with a common variable immunodeficiency (CVID)–like
phenotype, to date, only four different mutations have been
identified in a total of 15 patients [18]. Therefore, ICOS defi-
ciency accounts for less than 1% of approximately 2600
CVID-like patients with known gene defects (including
TNFRSF13B (80%), TNFRSF13C (4%), LRBA (2.5%), and
PIK3CD (2.5%)) [12–17, 19].
Here we report 7 new patients presenting with four novel
ICOSmutations resulting in a CVID phenotype, including the
first 2 cases ever reported of ICOS deficiency due to a mis-
sense mutation located within the helical domain of the pro-
tein, and another 2 patients with a compound heterozygous
mutations, one of which is located at a splice site. We com-
pared the clinical and immunological features of these patients
with previously published cases. Furthermore, we show that
inflammatory complications associated with ICOS deficiency
might be due to a skewed Th1 response, resulting from exces-
sive IL-12 production caused by the failure to downregulate
ICOSL expression on antigen presenting cells, including den-
dritic cells and monocytes. Finally, we report on treatment
outcome following a trial of the IL-12/23 blocker
ustekinumab in a patient with granulomatous complications.
Materials and Methods
Patients and Clinical Evaluation
Evaluation of medical records was carried out after obtaining
written informed consent, performed in accordance with the
guidelines of the ethics committees or the Institutional Review
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Boards of participating institutes at St. James’s University
Hospital, University College London (Royal Free Hospital),
and the Tehran University of Medical Sciences. All patients
were diagnosed as antibody deficient based on the updated
diagnostic criteria of ESID (the European Society for
Immunodeficiencies, http://esid.org/WorkingParties/Registry/
Diagnosis-criteria) [20] and AAAAI (The American
Academy of Allergy, Asthma and Immunology) practice
parameter for the diagnosis and management of primary
immunodeficiency [21]. After confirmation of diagnosis,
patients were classified according to the International Union
of Immunological Societ ies ( IUIS) and Primary
Immunodeficiency Diseases Committee updated classifica-
tion [11]. An evaluation sheet was used to summarize the
demographic information of patients including gender, ethnic-
ity, place and date of birth, medical history including the date
of diagnosis and record of other diseases, clinical manifesta-
tions, relevant laboratory tests, and family history.
Routine Immunological Assays
Complete blood count, lymphocyte subpopulations, serum Ig
levels, and specific antibody responses were measured as pre-
viously described [22–25].
Genetic Evaluation and In Silico Analysis
Whole exome sequencing (WES) was performed according to
established protocols [19, 22, 26]. The pathogenicity of all dis-
ease attributable gene variants was re-evaluated using the up-
dated guideline for interpretation of molecular sequencing by
the American College of Medical Genetics and Genomics
(ACMG), considering allele frequency in the population data-
bases, computational data, immunological/functional data, famil-
ial segregation and parental data, and clinical phenotyping [27].
Existing databases including the 1000 Genome; Exome
Aggregation Consortium; National Heart, Lung, and Blood
Institute exome variant server; and Greater Middle East
Variomewere used for filtering based on the population frequen-
cy for any given variant for all families. ICOS has a gene damage
index of 1.51 and a mutation significance cutoff of 5.374 [28].
The combined annotation-dependent depletion scores [29] for
the ICOS variants identified in the patients were calculated and
compared with the gene-specific mutation significance cutoff.
Confirmatory Sequencing
Genomic DNA was used in PCR employing exon-specific
primers (Supplementary Table E1). The PCR products were
purified using the QIAquick gel extraction kit (Qiagen) and
subsequently sequenced at Macrogen Inc. The sequences
were analyzed using the Lasergene software package
(DNAStar).
Th1/Th2 Phenotyping, ICOS, ICOSL, and CTLA4
Expression
Peripheral blood mononuclear cells (PBMCs) from pa-
tients and healthy donors were separated using a density
gradient method (Lymphoprep™, Alere Technologies,
Norway) from ethylenediaminetetraacetic acid (EDTA)
anticoagulated peripheral blood. Red cell lysis with ammo-
nium chloride was performed for Th1/Th2 phenotyping.
The isolated cells were washed twice by Dulbecco’s
phosphate-buffered saline (DPBS) then labeled with a pan-
el of monoclonal antibodies for immunophenotyping.
Analysis with multi-parameter 15 colors flow cytometry
panel was performed. The data was acquired on the
Becton Dickinson (BD) LSR II flow cytometer or BD
FACSLyric instruments, and the data was analyzed using
the BD FACSDiva software version 8.0. (for gating
strategy please see Supplementary Fig. E1).
For PBMCs stimulation, cells were incubated in RPMI
1640 Medium, GlutaMAX™ Supplement 10% fetal calf se-
rum (FCS) all from (Thermofisher, USA) at density of 1 × 106
cells/ml, and were stimulated using 5 μg/ml for phytohemag-
glutinin (PHA) 10 μg/ml, lipopolysaccharide (LPS) 10 ng/ml
both from (Sigma-Aldrich) and/or crosslinking beads of Anti-
Biotin MACSiBead particles and biotinylated antibodies
against human CD2, CD3, and CD28, were used as recom-
mended by manufacturer 1 cell/1 bead (Miltenyi Biotec,
Germany). Cells were analyzed using a multi-parameter flow
and for ICOSL surface expression based on the gating
strategy.
Cell surface and intracellular levels of CTLA4 were mea-
sured on T effector cells (CD3+ CD4+ CD25+) and regula-
tory (CD3+ CD4+ CD25hi Foxp3+) T cells using antibody
staining and flow cytometry. Peripheral blood mononuclear
cells were isolated by centrifugation (400g for 20 min) over
Lymphoprep (Cedar lane) and washed in TC199 tissue cul-
ture medium. Cells were stained both prior to culture (fresh),
and following culture in 96-well plates in triplicate in the
presence of PHA (Sigma, 2.5 μg/ml) for 48 h at 37 °C. For
cell surface expression of CTLA4, cells were stained with
CD3, CD4, CD25, and CTLA4, prior to fixation, perme-
abilization, and staining with FOXp3 antibody. For intracel-
lular staining of CTLA4, surface stained (CD3+ CD4+
CD25+) PBMC were fixed and permeabilized using BD
Pharmingen human FoxP3 buffer set (Cat No. 560098) ac-
cording to manufacturer’s instructions. Cells were subse-
quently stained with Foxp3/CTLA4 antibodies for 30 min
at room temperature prior to the final washing steps and
suspension in PBS/formaldehyde. Data acquisition was per-
formed using a FACS Canto II flow cytometer, using the
FACSDiva software with approximately 104 CD4+ T cells
acquired. For all details regarding specific antibodies used
for flow cytometry, please see Supplementary methods.
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Functional Analysis of Cytokine Production
Whole blood of patient and controls was diluted 1:5 in RPMI
into 96-well F plates (Corning) and activated by single stim-
ulation with phytohemagglutinin (PHA, 10 μg/ml; Sigma-
Aldrich) or LPS (1 μg/ml, List Biochemicals) alone or by
co-stimulation with IFN-γ (2 × 104 IU/ml, Imukin,
Boehringer Ingelheim), and supernatants were taken after
24 h incubation at 37 °C/5%CO2. Cytokines were measured
bymultiplexed bead array (IFN-γ, TNF-α, IL-12, IL-10, IL-6,
IL-17A, IL-1β, R+D Systems Fluorokinemap) on a Luminex
analyzer (Bio-Plex, Bio-Rad, UK).
Statistical Analysis
Statistical analyses were performed using the SPSS software
package, version 22 (SPSS Inc., Chicago, IL, USA). Two-way
ANOVA statistical test was used for comparison of cytokine
production between patients and controls (p < 0.05). Kaplan-
Meier curve and 95% confidence interval survival analysis
were utilized for prognosis evaluation of the patients.
Results
Genetic Diagnosis, Mutation Analysis, and Protein
Expression
We combined the information from previously published
cases (P1–P15) [12–17] and our new patients (P16–P22) to
provide an up to date clinical overview of ICOS deficiency.
Since all probands were diagnosed clinically with
hypogammaglobulinemia, the known genes associated with
antibody deficiency were excluded using next-generation se-
quencing (Supplementary Table E2) [19]. Three patients (P16,
P17, and P18), all of the Pakistani background but not from
the same kindred, were found to have a novel homozygous
deletion c.323_332del (p.F108TfsX11) (Supplementary Fig.
E2). To our knowledge, P19 and P20 are the first ICOS defi-
ciencies caused by compound heterozygous mutations
(p.F119S and c.58+1G>A), one of which is a splice site mu-
tation (Supplementary Fig. E2). P21 and P22 were homozy-
gous for a novel missense mutation (p.V151L, Fig. 1,
Supplementary Fig. E2, and Fig. E3within the helical domain.
In silico analysis of the identified missense mutations
(p.F119S and p.V151L) showed that both are located in highly
conserved residues and both damage the formation of protein
and nucleotide binding regions surrounding the helical do-
main, suggesting the production of a misfolded protein (Fig.
1 and supplementary Fig. E3).
We studied ICOS protein expression in P16, P17, P19, and
P20. As expected, neither P16 nor P17 (with homozygous
deletion mutations) had any expression of ICOS on CD4+ T
cells following stimulations with anti-CD3 and PHA
(Supplementary Fig. E4). There was also no ICOS expression
in P19 or P20 despite the fact that the point mutation
(p.F119S) was not predicted to lead to a complete loss of
protein expression. Interestingly, F119S mutant was described
previously as part of in vitro study to map out ligand binding
sites for ICOS. This mutant can be expressed in vitro; howev-
er, this was in a complex with CH2-CH3 portion of human
IgG1. The mutated protein, although expressed still failed to
bind to B7-H2 [30].
Clinical and Immunological Overview of ICOS
Deficiency
The summary of clinical and immunological features of the 7
new cases is shown in Table 1. Detailed clinical reports are
provided in Supplementary results. All patients had a prior
diagnosis of antibody deficiency, with 6/7 labeled as CVID.
The clinical features observed in all patients with ICOS
deficiency (Table 1, Supplementary Tables E3–7, and Fig. 2)
are heterogeneous with the age of presentation ranging from
early infancy to 39 years. The majority (70%, 14/20) present-
ed at childhood or before 13 years of age, but due to the
piecemeal progression and mild phenotype, most of the pa-
tients were diagnosed in adulthood (68.1%, 15/22). The dis-
ease phenotype can broadly be divided into an infectious phe-
notype (77.2%), an enteropathy phenotype (54.5%), a lym-
phoproliferative phenotype (40.9%), and an autoimmunity
phenotype (31.8%, Fig. 2b).
The infections include encapsulated bacterial infections
due to hypogammaglobulinemia mainly in the respiratory sys-
tem, but also viral infections (particularly by the
Herpesviridae family) and opportunistic fungal and parasitic
infections, suggesting some degree of combined immunode-
ficiency (Supplementary Tables E4–5).Pneumocystis jirovecii
pneumonia was also described in one report [17]. A wide
range of autoimmune diseases has been documented, includ-
ing autoimmune cytopenia, autoimmune interstitial pneumo-
nitis, inflammatory bowel disease, psoriasis, and rheumatoid
arthritis.
Enteropathy usually manifested as chronic diarrhea without
significant growth retardation. The lymphoproliferative spec-
trum consisted of lymphadenopathy, hepatosplenomegaly,
granulomatous lesions, and nodular lymphoid hyperplasia.
Carcinoma of the vulva associated with human papillomavi-
rus (HPV) infection was also reported in one patient (P1) and
squamous cell carcinoma in one patient (P6). It appears that
chronic diarrhea dominated in patients presenting before ado-
lescence and was associated with viral infections (P12–P15
and P19–21), while respiratory infections and cutaneous le-
sions were more prominent in older patients (P1–P10).
However, single episodes of pneumonia in childhood did oc-
cur in some patients prior to developing recurrent respiratory
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and other complications and a subsequent diagnosis of CVID
in adulthood (P1–P9). This temporal gap in presentation,
where symptoms occur in early life followed by a dormant
period, occurred in one third of the patients (5 out of 15,
Table 1) reported to date.
P16 had further unusual complications, not previously de-
scribed in ICOS deficiency. He developed well-documented
delayed type hypersensitivity reactions to several different
antibiotic classes (Supplemental results, Fig. E5a).
Interestingly, lymphocyte transformation assays to all impli-
cated antibiotics were negative (Supplementary Fig. E5b).
Immunological Features
Human ICOS deficiency abrogates the germinal center reac-
tion and provides a monogenic cause of CVID immunological
phenotype in most of the patients. However, hyper IgM phe-
notype has also been reported in two patients (P11 and P12,
9.0%). Antibody responses to vaccination using different an-
tigens result in non-protective IgG production (especially
against peptide antigens); however, one patient (P22) showed
intact specific antibody production.
Peripheral B cell counts may be reduced, particularly in
adulthood and accompanied by a reduction in naïve B lym-
phocyte counts (8 out of 19, 42.1%); whereas, almost all
ICOS-deficient patients present an increased level of naïve B
lymphocytes (93.7%) at the time of diagnosis. ICOS-deficient
patients show reduced numbers of both CD27+ switched
memory B cells (100%) and non-switched memory B cells
(88.8%). The ICOS-deficient patients show an almost normal
distribution of T cell subpopulations (except for a decreased
number of CXCR5+CD4+ T helper cells in the all studied
patients and an inverted CD4+/CD8+ ratio in 33.3%).
Natural killer (NK) lymphopenia was also recorded in 38%
of studied patients, suggesting a degree of innate immune
defects in the ICOS deficiency. Table 1 and Supplementary
Tables E6–7 depict all immunological manifestation of the 22
ICOS-deficient patients reported to date.
Functional Analysis of Cytokine Responses
Poor IL-10 and IL-17 production were previously demonstrat-
ed in ICOS deficiency [14]. Furthermore, one report showed
inadequate production of pro-inflammatory cytokines, IL-1,
IL-6, and TNF [15]. We tested the cytokine production using
whole blood from P16, P17, P19, and P20. We replicated
significantly poorer IL-10 and IL-17 responses to polyclonal
T cell stimulation with PHA in all patients when compared
with HC. However, we found that production of IL-1ß and
TNF was comparable with HC in response to LPS and
IFNγ/LPS. Interestingly, ICOS-deficient patients showed sig-
nificantly higher IL-6 production following LPS or combined
Fig. 1 ICOS variants diagnosed in combined immunodeficiency. a
Schematic view of the ICOS exons and domains representing the rate
of missense and loss of function mutation among a normal population
(extracted from genomAD), variants diagnosed in patients with ICOS
deficiency. b Black and red mutations marks refer to previously
reported and newly identified mutations, respectively. c Multiple
sequence alignments representing conservation within positions of
newly observed missense mutations (p.F119S and p.V151L) in the
ICOS protein. d 3D structure of ICOS protein representing the location
of the missense mutations in helical domain of the protein
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IFNγ/LPS stimulation of the whole blood. Similarly, signifi-
cantly elevated production of IL-12 was seen in almost all
patients compared with HC after combined IFNγ/LPS stimu-
lation (Fig. 3).
ICOSL Expression
Monocytes and dendritic cells (DCs) are typically the main
producers of IL-12. We wondered whether lack of ICOS ex-
pression on T cells, and therefore lack of engagement with
ICOSL expressed by the activated monocytes and DC, might
be causing a persistent activation of the latter, and increased
production of IL-12.We therefore investigated ICOSL expres-
sion on monocytes from the patients and HC following stim-
ulation with LPS over several days. We found significantly
increased expression of ICOSL on patient monocytes at 24 h,
48 h, and 72 h time points, with the levels returning to those
comparable with HC at day 4 (120 h) (Fig. 4a). This finding is
consistent with a murine model which shows that both ICOS
and ICOSL depend on their mutual interaction to regulate
their surface expression [31].
TH1/TH2 Profile
As IL-12 has an important role in driving Th1 differentiation,
we performed detailed T cell phenotyping of P16 and P17. In
both cases, there was a significant skewing of the T cell phe-
notype towards Th1 (Fig. 4b). The ratio of Th1/Th2 cells was
significantly elevated compared with ICOS sufficient primary
antibody deficiency patients (p = 0.0002) and healthy controls
(p < 0.0001). The predominance of Th1 phenotype in ICOS
Fig. 2 a Kaplan-Meier survival
rate for ICOS deficiency. b
Clinical features of ICOS
deficiency
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deficiency was seen in both T follicular helper Tcells and non-
follicular T helper cells.
CTLA4 Expression
Lastly, we examined the expression of CTLA4 on all CD4+ T
cells and specifically on the regulatory T cells from P16 and
P17. Since CTLA4 expression on T cells is not constitutive
but dependent on their activation, we postulated that CTLA4
expression in ICOS deficiency might be impaired due to in-
adequate Tcell activation. We stimulated Tcells from P16 and
P17 with PHA (Sigma, 2.5 μg/ml) for 48 h at 37 °C and
examined the intracellular and extracellular expression of
CTLA4 at the baseline and following stimulation with PHA.
We found that in both patients, CD4 effector T cells (CD3+
CD4+ CD25+) failed to upregulate CTLA4. A similar finding
was observed in regulatory T cells (CD3+ CD4+ CD25hi
FOXp3+, CD127−), which interestingly showed comparable
intracellular expression of CTLA4 with HC, but the expres-
sion of CTLA4 on the cell surface was significantly reduced
(Fig. 5).
Treatment Outcomes
Regarding the newly identified cohort, 6/7 patients received
intravenous Ig (IVIg), one patient was only on prophylactic
antibiotic treatment (Table 1), and one (P17) died at the age 53
from overwhelming salmonella sepsis. A previous report de-
scribes premature death in three patients (malignancy in P1,
capillary leak syndrome, and toxic epidermal necrolysis after
hematopoietic stem cell transplantation (HSCT) in P14, and
due to an immunodeficiency unrelated event in P4). However,
transplantation has been successfully used in two ICOS pa-
tients (P6 and P12). Although the Kaplan-Meier 55-year sur-
vival rate of ICOS deficiency is estimated to be 81% (CI 0.72–
1.0) the rate of mortality seems higher in patients with
Fig. 3 Cytokine production after whole blood stimulation: healthy controls (C gray circles, n = 59) and patients (P16, red circles; P17, red triangles; P18,
red squares; P20, red diamonds). Statistical analysis was done with two-tailed Mann-Whitney tests using the GraphPad Prism software V8.02
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enteropathy phenotype (Fig. 2a); however, this is not statisti-
cally significant. Moreover, death in infancy was also reported
in siblings of patients (in P10, P11, and P17).
Interestingly, one female patient was reported to be asymp-
tomatic despite being homozygous for a 1815 base pair dele-
tion (P8), but Ig substitutions have been administrated on this
patient [18]. P18 in our cohort, showing very mild presenta-
tion and only respiratory infections was also female. Of note
patients diagnosed to date with symptomatic ICOS deficiency
are mainly males (14/22, 63.6%). This discrepancy in the dis-
ease severity was also seen in two other sibling pairs in the
new cohort. Patient P19 has a relatively mild and predomi-
nantly infectious phenotype, unlike his sister (P20) who had
severe and multiple inflammatory/autoimmune complica-
tions. Disease severity varied in a similar fashion between
P21 and P22, despite them sharing the same novel homozy-
gous missense mutation. This suggests that a wide range of
clinical presentations is probably the result of other modifying
factors.
Patient 16, who had multiple inflammatory and autoim-
mune complications, received ustekinumab (Stalara)
(260 mg IV followed by 90 mg IV after 8 weeks followed
by 90 mg IV every 12 weeks) having previously failed high
dose IVIg, corticosteroids (Prednisolone 30 mg), and azathio-
prine to treat multi-linage cytopenias due to granulomatous
bone marrow inflammation. As we demonstrated high
ex vivo whole blood IL-12 production in this patient, associ-
ated with the skewed Th1 profile, we believed that a combined
and targeted IL12/IL23 blockade provided by ustekinumab
would help to resolve the inflammatory complications without
further significant immunosuppressive effect. Unfortunately,
despite receiving 6 months of treatment, no significant im-
provement in the platelet count, neutrophil count, or hemoglo-
bin levels was observed.
Discussion
The clinical features of ICOS deficiency patients that have
been reported worldwide, including the 7 described in this
study, suggest that there is no clear genotype-phenotype cor-
relation since patients with the same mutation may exhibit
different disease severity and complications or even be
asymptomatic; whereas, the immunological features are more
consistent. Hypogammaglobulinemia is almost universal, typ-
ically associated with abnormal germinal center development
and poorly developed memory B cell compartment resulting
in a diminished secondary immune response [12, 16, 17]. T
cell lymphopenia appears to be rare as we found in our cohort,
but there is usually a normal distribution of T cell subpopula-
tions, and T cell proliferative responses are typically pre-
served. However, it is evident that the lack of ICOS expression
on activated T cells decreases IL-10 and IL-17 synthesis and
results in a lack of T cell support for B cell maturation and
formation of germinal centers. Patients with ICOS deficiency
may have either normal [12] or reduced [15] proportions of
both CD4+ and CD8+ memory T cells, and it has been sug-
gested that ICOS is required for the proliferation and survival
of memory T cell subsets in humans [15]. In a recent report on
memory T cells for two ICOS-deficient patients, the propor-
tion of both central and effector memory cells in helper and
cytotoxic T cells were decreased as a consequence of a homo-
zygous p.F95fsX26 mutation (P10–P11) [15].
Fig. 4 ICOSL expression on monocytes and Th1 and Th2 ratios. a. Time
line changes (0–120 h) ICOSL level fold change onmonocytes in patients
(n = 4) determined by flow cytometry compared with health controls (n =
3) following LPS stimulation. b Mean with SD of the ratio of Th1/Th2
cells within the memory Tcell population (CD45RANeg CD4 Tcells) of
ICOS deficiency (n = 3), ICOS sufficient primary antibody deficiency
(n = 6), and healthy controls (n = 7). Th1 cells were gated as CD183+
CD196− helper memory T cells and Th2 cells were gated as CD183
−CD196− helper memory T cells. Unpaired t test and p values provided.
The detailed gating strategy is provided in Fig. E4.
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In this study, we have replicated poor IL-10 and IL-17
cytokine responses. However, we have also shown that the
production of pro-inflammatory cytokines is preserved and
in some cases enhanced. The previous study which reported
diminished IL-1β, IL-6, and TNF production in ICOS-
deficient patients used different experimental conditions based
on isolated T cells [15]. We performed these investigations
using a whole blood assay, which contained monocytes and
DCs, and typical producers of pro-inflammatory cytokines.
We showed that production of TNF and IL-1β is comparable
with that in HC, but that there is significantly increased pro-
duction of IL-6 in response to LPS, and particularly increased
production of IL-12 following stimulation with LPS and
INFγ. We then went on to demonstrate that monocytes of
ICOS-deficient patients have significantly increased expres-
sion of ICOSL, suggesting that enhanced production of IL-12
might in part result from the failure to downregulate ICOSL.
The importance of downregulation of ICOSL by interaction
with ICOS as a way of regulating inflammatory responses was
previously shown in a murine model. The antigen presenting
cells (APCs) of ICOS-transgenic mice (high constitutive
expression of ICOS on T cells) showed significant downreg-
ulation of ICOSL and consequent inability to generate appro-
priate cytokine responses [31]. The opposite seems to be true
in the case of ICOS-deficient patients, where sustained expres-
sion ICOSL expression is associated with prolonged activa-
tion of APCs and enhanced production of inflammatory
cytokines.
The excessive IL-12 production we have seen in our pa-
tients seems to be clinically relevant since this was associated
with skewing of helper T cells towards a predominantly Th1
phenotype. A recent study in CVID patients showed that
skewed Th1 phenotype of follicular helper cells was associat-
ed with immune dysregulation and inflammatory complica-
tions [32].We used findings from our study to select a targeted
therapy for one of the patients (P16) with several inflamma-
tory complications (granuloma role of IL-12). Unfortunately,
in this case, selective blockade of IL-12 with ustekinumab did
not produce the desired outcome. There are number of possi-
ble reasons for this, including wrong dose or regimen.
We have also shown reduced CTLA4 surface expression
on the effector CD4+ Tcells and Tregs. Reduced expression of
Fig. 5 CTLA expression on a
Tregs and b CD4+ T effector
cells. PBMC were isolated from
healthy control (HC) and patients
(P16 and P17). Cells were stained
both prior to culture (fresh), and
following culturing in 96-well
plates in triplicate in the presence
of PHA (Sigma, 2.5 μg/ml) for
48 h at 37 °C. Surface and
intracellular levels of CTLA4
were assessed on both Tregs and
effector T cell populations. The
figure represents the average of 3
separate experiments. S, surface
expression; I, intracellular
expression. Statistical analysis
was done with unpaired t test and
p values provided tests using the
GraphPad Prism software V8.02
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this inhibitory receptor due to heterozygous germline muta-
tions in CTLA4 is known to cause severe immune dysregula-
tion [33, 34]. It is therefore possible that in ICOS deficiency,
in addition to impaired IL-10 production, reduced CTLA4
expression is relevant for the pathogenesis of autoimmune
and inflammatory complications. Abatacept (CTLA4-Ig) has
been used successfully to treat patients with CTLA4
haploinsufficiency [35] and LRBA deficiency [36], and con-
sidering our findings, abatacept might also be a therapeutic
option for selective patients with ICOS deficiency.
We thus conclude that ICOS still accounts for a small but
growing group of patients with combined PID. The clinical
phenotypes associated with this genetic diagnosis continue to
expand. Immune dysregulation resulting in overlapping in-
flammatory and immunodeficiency complications is typical
for many patients. Improved understanding of this process
might lead to improved targeted therapies in the future.
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